|
DK0574466T3
(da)
|
1991-03-05 |
1999-11-08 |
Wellcome Found |
Udtrykkelse af rekombinante proteiner i svækkede bakterier
|
|
AU661360B2
(en)
|
1991-10-25 |
1995-07-20 |
Immunex Corporation |
Novel cytokine
|
|
US7405270B2
(en)
|
1991-10-25 |
2008-07-29 |
Immunex Corporation |
CD40-Ligand lacking native-pattern glycosylation
|
|
US5962406A
(en)
|
1991-10-25 |
1999-10-05 |
Immunex Corporation |
Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
|
|
US5981724A
(en)
|
1991-10-25 |
1999-11-09 |
Immunex Corporation |
DNA encoding CD40 ligand, a cytokine that binds CD40
|
|
ATE173166T1
(de)
|
1992-09-04 |
1998-11-15 |
Univ Saskatchewan |
Neue bakterielle impfstoffe unter verwendung von impfstämmen von pathogenen bakterien
|
|
AU1059095A
(en)
|
1993-11-24 |
1995-06-13 |
Australian National University, The |
Treatment of viral disease with cd40l peptide
|
|
DK0812206T3
(da)
|
1995-03-01 |
2002-09-09 |
Immunex Corp |
Fremgangsmåde til stimulering af en immunrespons
|
|
MX9709447A
(es)
|
1995-06-07 |
1998-02-28 |
Immunex Corp |
Nueva muteina cd4ol.
|
|
US6479258B1
(en)
|
1995-12-07 |
2002-11-12 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines
|
|
US6713279B1
(en)
|
1995-12-07 |
2004-03-30 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines and enzymes
|
|
US6306387B1
(en)
|
1997-05-29 |
2001-10-23 |
The Research Foundation Of State University Of New York |
Antigen delivery system
|
|
US20030045492A1
(en)
|
1997-08-13 |
2003-03-06 |
Tang De-Chu C. |
Vaccination by topical application of recombinant vectors
|
|
US6969609B1
(en)
|
1998-12-09 |
2005-11-29 |
The United States Of America As Represented By The Department Of Health And Human Serivces |
Recombinant vector expressing multiple costimulatory molecules and uses thereof
|
|
CA2223225A1
(en)
|
1997-11-28 |
1999-05-28 |
Canadian Red Cross Society |
Method for inhibiting in vivo immune response
|
|
CA2313805A1
(en)
|
1997-12-19 |
1999-07-01 |
Immunex Corporation |
Method for reducing susceptibility to hiv infection
|
|
GB9806449D0
(en)
|
1998-03-25 |
1998-05-27 |
Peptide Therapeutics Ltd |
Attenuated bacteria useful in vaccines
|
|
US6190669B1
(en)
|
1998-05-13 |
2001-02-20 |
University Of Maryland, Baltimore |
Attenuated mutants of salmonella which constitutively express the Vi antigen
|
|
IT1299583B1
(it)
|
1998-05-19 |
2000-03-16 |
Vander Way Limited |
Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
|
|
PT1108034E
(pt)
|
1998-09-04 |
2008-11-14 |
Emergent Product Dev Uk Ltd |
Mutantes de spi2 de salmonela atenuados como transportadores de antigénios
|
|
US7300774B1
(en)
|
1999-12-09 |
2007-11-27 |
The Regents Of The University Of California |
Multimeric fusion proteins of the TNF superfamily ligands
|
|
EP1067194A1
(en)
|
1999-04-16 |
2001-01-10 |
F. Hoffmann-La Roche Ag |
Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
|
|
WO2000063395A1
(en)
|
1999-04-16 |
2000-10-26 |
F. Hoffmann-La Roche Ag |
Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
|
|
EP1246643A4
(en)
|
1999-10-14 |
2005-05-11 |
Jeffery A Ledbetter |
DNA VACCINES ENCODING ANTIGEN ASSOCIATED WITH CD40-BINDING DOMAIN
|
|
TR200401569T4
(tr)
|
1999-12-28 |
2004-07-21 |
Akzo Nobel N.V. |
Flagelin ya da flagelle'ya karşı antikorların oluşumuna sebep olmayan salmonelle aşısı
|
|
ATE412427T1
(de)
|
2000-02-02 |
2008-11-15 |
Us Health |
Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff
|
|
AU5695701A
(en)
|
2000-03-17 |
2001-10-03 |
Upjohn Co |
Salmonella vaccine materials and methods
|
|
GB0015426D0
(en)
|
2000-06-24 |
2000-08-16 |
Univ Southampton |
Method for generating soluble highly multimeric proteins
|
|
US20030165538A1
(en)
|
2000-06-26 |
2003-09-04 |
Maxygen Incorporated |
Methods and compositions for developing spore display systems for medicinal and industrial applications
|
|
AU2002221780A1
(en)
|
2000-10-31 |
2002-05-15 |
F.Hoffmann-La Roche Ag |
Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
|
|
US7220723B2
(en)
|
2001-05-15 |
2007-05-22 |
The Feinstein Institute For Medical Research |
Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
|
|
EP1392844A4
(en)
|
2001-05-15 |
2006-09-06 |
Long Island Jewish Res Inst |
USE OF HMG FRAGMENTS AS ANTI-INFLAMMATORY AGENTS
|
|
ATE438710T1
(de)
|
2001-05-15 |
2009-08-15 |
Ortho Mcneil Janssen Pharm |
Ex-vivo-priming zur erzeugung cd40-ligand spezifischer zytotoxischer t-lymphozyten zur behandlung von autoimmun- und allergischen erkrankungen
|
|
ITMI20011986A1
(it)
|
2001-09-25 |
2003-03-25 |
San Raffaele Centro Fond |
Metodo e composizione per l'attivazione di cellule presentanti l'antigene
|
|
JP2005511770A
(ja)
|
2001-12-19 |
2005-04-28 |
アルケド バイオテック ゲーエムベーハー |
Ｈｍｇｂタンパク質およびｈｍｇｂタンパク質をコードする核酸の使用方法
|
|
MXPA04005909A
(es)
|
2001-12-21 |
2005-05-17 |
Immunex Corp |
Polipeptidos recombinantes.
|
|
AU2003215254A1
(en)
|
2002-02-13 |
2003-09-04 |
Immunology Laboratories, Inc. |
Compositions and methods for treatment of microbial infections
|
|
US6923958B2
(en)
|
2002-03-02 |
2005-08-02 |
The Scripps Research Institute |
DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
|
|
ATE556596T1
(de)
|
2002-04-15 |
2012-05-15 |
Univ St Louis |
Regulierte attenuierung von lebendimpfstoffen zur verbesserung der kreuzimmunitätsschutzfunktion
|
|
US7495090B2
(en)
|
2002-05-23 |
2009-02-24 |
The Regents Of The University Of California |
Nucleic acids encoding chimeric CD154 polypeptides
|
|
JP2006506441A
(ja)
|
2002-11-20 |
2006-02-23 |
ノース ショア−ロング アイランド ジュ−イッシュ リサ−チ インスティチュ−ト |
免疫応答を増大させるためのｈｍｇｂポリペプチドの使用
|
|
CA2506328A1
(en)
|
2002-11-20 |
2004-06-03 |
Critical Therapeutics, Inc. |
Use of hmgb fragments as anti-inflammatory agents
|
|
US20040141948A1
(en)
|
2002-11-20 |
2004-07-22 |
Critical Therapeutics, Inc. |
Use of HMGB fragments as anti-inflammatory agents
|
|
US20040156851A1
(en)
|
2002-11-20 |
2004-08-12 |
Critical Therapeutics, Inc. |
HMGB1 combination therapies
|
|
US20060014248A1
(en)
|
2003-01-06 |
2006-01-19 |
Xencor, Inc. |
TNF super family members with altered immunogenicity
|
|
US20050181994A1
(en)
|
2003-01-06 |
2005-08-18 |
Xencor, Inc. |
Novel variants of CD40L protein
|
|
US7696169B2
(en)
|
2003-06-06 |
2010-04-13 |
The Feinstein Institute For Medical Research |
Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
|
|
US7754209B2
(en)
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
|
WO2005025604A2
(en)
|
2003-09-10 |
2005-03-24 |
The General Hospital Corporation |
Use of hmgb and hmgb fragments to decrease specific immune response
|
|
CA2882022A1
(en)
|
2003-09-11 |
2005-03-24 |
Walter Newman |
Monoclonal antibodies against hmgb1
|
|
EP1673389A2
(en)
|
2003-10-10 |
2006-06-28 |
Xencor Inc. |
Novel variants of cd40l protein
|
|
JP2008501625A
(ja)
|
2003-11-21 |
2008-01-24 |
エース バイオサイエンシズ エー／エス |
表在Ｃａｍｐｙｌｏｂａｃｔｅｒｊｅｊｕｎｉポリペプチド
|
|
CA2548347A1
(en)
|
2003-12-11 |
2005-06-30 |
Sidney Kimmel Cancer Center |
Methods for generating immunity to antigen
|
|
US8828957B2
(en)
|
2003-12-11 |
2014-09-09 |
Microvax, Llc |
Methods for generating immunity to antigen
|
|
EP1740604A2
(en)
|
2004-04-27 |
2007-01-10 |
Intercell AG |
Td antigens
|
|
WO2005113598A2
(en)
|
2004-05-21 |
2005-12-01 |
Xencor, Inc. |
Tnf super family members with altered immunogenicity
|
|
WO2006083301A2
(en)
|
2004-06-17 |
2006-08-10 |
Medimmune, Inc. |
Immunogenic compositions comprising hmgb1 polypeptides
|
|
AU2005321630A1
(en)
*
|
2004-07-02 |
2006-07-06 |
Metanomics Gmbh |
Process for the production of fine chemicals
|
|
WO2006012373A2
(en)
|
2004-07-20 |
2006-02-02 |
Critical Therapeutics, Inc. |
Combination therapies of hmgb and complement inhibitors against inflammation
|
|
ATE489455T1
(de)
|
2004-10-07 |
2010-12-15 |
Argos Therapeutics Inc |
Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung
|
|
US8513008B2
(en)
|
2004-10-07 |
2013-08-20 |
Argos Therapeutics, Inc. |
Mature dendritic cell compositions and methods for culturing same
|
|
GB0423681D0
(en)
|
2004-10-26 |
2004-11-24 |
Sec Dep For Environment Food & |
Vaccine and nucleic acids
|
|
WO2006105972A1
(en)
|
2005-04-07 |
2006-10-12 |
Universite Libre De Bruxelles |
Transgenic organism expressing cd40l and uses thereof
|
|
WO2006130525A2
(en)
|
2005-05-31 |
2006-12-07 |
Sidney Kimmel Cancer Center |
Methods for immunotherapy of cancer
|
|
WO2007011606A2
(en)
|
2005-07-18 |
2007-01-25 |
Critical Therapeutics, Inc. |
USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
|
|
CN101330928B
(zh)
|
2005-10-07 |
2012-11-14 |
西马生物医学计划公司 |
用于预防和治疗丙型肝炎的免疫刺激剂组合
|
|
CA2628837C
(en)
|
2005-11-07 |
2018-11-27 |
Sidney Kimmel Cancer Center |
Cd40 ligand fusion protein vaccine
|
|
WO2007054658A1
(en)
|
2005-11-14 |
2007-05-18 |
King's College London |
Control of immune responses
|
|
WO2007130725A2
(en)
|
2006-02-06 |
2007-11-15 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Use of hmgb1 for protection against ischemia reperfusion injury
|
|
CU23576A1
(es)
|
2006-02-28 |
2010-09-30 |
Ct Ingenieria Genetica Biotech |
Antígenos vacunales quiméricos contra el virus de la influenza aviar
|
|
WO2007103048A2
(en)
|
2006-03-01 |
2007-09-13 |
Regents Of The University Of Colorado |
Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
|
|
US8802419B2
(en)
|
2006-03-02 |
2014-08-12 |
University Of Massachusetts |
Modified pathogens for use as vaccines
|
|
WO2007130520A2
(en)
*
|
2006-05-04 |
2007-11-15 |
Abmaxis Inc. |
Cross-species and multi-species display systems
|
|
US9439959B2
(en)
|
2006-07-27 |
2016-09-13 |
Takeda Vaccines, Inc. |
Chimeric influenza virus-like particles
|
|
EP2056872A4
(en)
|
2006-08-09 |
2016-12-21 |
Medimmune Llc |
INFLUENZA HEMAGGLUTININE AND NEURAMINIDASE VARIANTS
|
|
PT2066339E
(pt)
|
2006-09-18 |
2014-10-31 |
Texas A & M Univ Sys |
Composições e métodos de potenciar respostas imunes
|
|
BRPI0718273A2
(pt)
*
|
2006-10-27 |
2013-11-12 |
Dow Agrosciences Llc |
Vacina para aves domésticas, para enterite necrótica, compreendendo um antígeno de toxina clostridium perfringens mutante, e métodos de produção da vacina
|
|
WO2008109825A2
(en)
|
2007-03-08 |
2008-09-12 |
Mayo Foundation For Medical Education And Research |
Inducing immune-mediated tumor cell death
|
|
WO2009009215A2
(en)
|
2007-05-02 |
2009-01-15 |
Emory University |
Enhancement of glycoprotein incorporation into virus-like particles
|
|
JP2011502165A
(ja)
|
2007-10-30 |
2011-01-20 |
ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー |
鞭毛細菌に対する免疫応答を強化する組成物および方法
|
|
DK2214701T3
(en)
|
2007-11-01 |
2016-12-12 |
Univ Arkansas |
CONFIGURATIONS AND METHODS FOR IMPROVING THE IMMUNE RESPONSES TO Eimeria
|
|
US8669113B2
(en)
|
2008-04-03 |
2014-03-11 |
Becton, Dickinson And Company |
Advanced detection of sepsis
|
|
JP5660889B2
(ja)
|
2008-04-30 |
2015-01-28 |
株式会社ジェノミックス |
末梢循環への骨髄由来多能性幹細胞動員薬
|
|
DK2329266T3
(en)
|
2008-09-11 |
2016-07-18 |
Pasteur Institut |
MONITORING AND INHIBITING INFECTION WITH HUMAN IMMUNE DEFECT VIRUS BY MODULATING HMGB1-DEPENDENT TRACTOR OF HIV-1 REPLICATION AND PERSISTENCE
|
|
US8163281B2
(en)
|
2009-03-04 |
2012-04-24 |
The Regents Of The University Of Michigan |
Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis
|
|
GB0917002D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Improved shigella blebs
|
|
US8956618B2
(en)
|
2010-01-21 |
2015-02-17 |
The Texas A&M University System |
Vaccine vectors and methods of enhancing immune responses
|
|
DK2365332T3
(da)
|
2010-03-10 |
2013-08-26 |
Pasteur Institut |
HMGB1- og anti-HMGB1-antistoffer i HIV-inficerede patienter, især med neurologiske lidelser
|
|
US8865653B2
(en)
|
2010-04-22 |
2014-10-21 |
Institut Gustave Roussy |
Method of treatment for immunogenic treatment resistant cancer
|
|
NZ604412A
(en)
|
2010-06-09 |
2015-01-30 |
Univ Arkansas |
Vaccine and methods to reduce campylobacter infection
|
|
WO2014028776A1
(en)
|
2012-08-15 |
2014-02-20 |
Zyngenia, Inc. |
Monovalent and multivalent multispecific complexes and uses thereof
|
|
NZ708065A
(en)
|
2012-10-29 |
2019-07-26 |
Univ Arkansas |
Novel mucosal adjuvants and delivery systems
|
|
HUE047484T2
(hu)
*
|
2013-02-14 |
2020-04-28 |
Univ Arkansas |
Készítmények és eljárások eimeria elleni immunválasz fokozására vagy eimeria-fertõzés korlátozására
|
|
CA2906079C
(en)
*
|
2013-03-15 |
2022-08-23 |
The Board Of Trustees Of The University Of Arkansas |
Compositions and methods of enhancing immune responses to enteric pathogens
|
|
AU2015269415A1
(en)
|
2014-06-05 |
2017-01-05 |
The Board Of Trustees Of The University Of Arkansas |
Antibody guided vaccines and methods of use for generation of rapid mature immune responses
|